Amendment to the Specification

Please amend the paragraph beginning on page 1 at line 1 and ending at line 5 as follows:

This application is a continuation of U.S. Serial No. 08/702,011, filed August 23, 1996, the entire disclosure of which is incorporated herein by reference. The present invention is directed to an injectable, intravenous pharmaceutical composition for the treatment of cancer.

Please amend the paragraph beginning on page 2 at line 23 and ending on page 3 at line 2 as follows:

The experimental results demonstrate that the intravenous composition of the present invention exert a strong abruptive effect on the membranes on cancer cells, such as leukemic cells. The intravenous composition of the present invention may also incorporate a pH-buffering agent in order to control the pH for effective and safe administration of the composition to patients. The pH-buffering agent is selected from the group consisting of hydrochloric acid (HC1), alkali hydroxide, such a sodium hydroxide, or carbonate solutions, as taught by Merck Index, 10th Ed. 1983, p. 117 (compound 824 - arsenic trioxide). It inhibits DNA/RNA synthesis and reduces the proliferation of the leukemic cells. The experiments, both *in vivo* and *in vitro* have demonstrated that the intravenous composition of the present invention is effective in destroying leukemic cells while inducing increased cell differentiation to produce normal cells. Additionally, the recovery of hematopoietic function is accelerated. It has also been found that the composition of the present invention can pass through the blood-brain barrier.